论文部分内容阅读
目的探讨未成熟网织红细胞指数(IRF)对乳腺癌患者化疗后骨髓抑制状态的临床价值。方法59例观察对象均为我院肿瘤科住院患者,均经病理组织学或细胞学证实。采用sysmex XE-2100全自动血细胞分析仪动态观察化疗过程中的外周血网织红细胞数和白细胞数。结果乳腺癌患者化疗后,79.8%的病例IRF的降低早于中性粒细胞数和血小板的降低(P<0.05)。骨髓造血功能恢复期,于化疗后的15 d IRF的出现或逐渐升高,较网织红细胞绝对数达到正常参考范围低线早15 d。结论IRF可作为评价乳腺癌患者化疗过程中骨髓造血功能受抑制和开始恢复的较敏感指标。
Objective To investigate the clinical value of immature reticulocyte index (IRF) in patients with breast cancer after chemotherapy for bone marrow suppression. Methods 59 cases were observed in our hospital oncology inpatients were confirmed by histopathology or cytology. Using sysmex XE-2100 automatic hematology analyzer dynamic observation of peripheral blood in the course of chemotherapy reticulocyte and white blood cell count. Results After chemotherapy, the IRF in 79.8% patients was earlier than that in neutrophils and platelets in patients with breast cancer (P <0.05). The recovery of bone marrow hematopoietic function, in the 15 d after chemotherapy, the incidence of IRF or gradually increased, compared with the number of reticulocytes reached the normal reference line as early as 15 d. Conclusion IRF can be used as a sensitive index to evaluate the inhibition and recovery of hematopoietic function in patients with breast cancer during chemotherapy.